Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Randomized Controlled Trial of MIB-626 (NAD-boosting Drug) vs. Placebo in Adults With COVID-19 Infection and Early Acute Kidney Injury

NCT05038488 is registered in ClinicalTrials.gov with Metro International Biotech, LLC as lead sponsor.

NCT NCT05038488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05038488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Randomized Controlled Trial of MIB-626 (NAD-boosting Drug) vs. Placebo in Adults With COVID-19 Infection and Early Acute Kidney Injury
Lead sponsor
Metro International Biotech, LLC
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2021
Completion date
August 17, 2023
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, stage 1 acute kidney injury